Even as India is poised to become the second largest manufacturer of active pharmaceutical ingredients (APIs) worldwide by 2010, the Hyderabad-based Aurobindo Pharmaceuticals Ltd is set to spearhead the growth through focusing on speciality products. The company, which is into both formulation and API manufacturing, has the largest API manufacturing capacity in India.
The company, which has its products in almost every therapeutic segments, has its stepwise strategy to become one among the world leaders in various speciality segments. The company already is a leading manufacturer of some of the APIs like Anti Retrovirals (ARVs) and anti-infectives with large portfolio of generic ARVs approved by US Food and Drug Administration (FDA) and World Health Organisation (WHO), Geneva.
"Today, our horizons are not limited by geographical or functional boundaries, when it comes to research, synthesis, manufacturing and marketing of a diverse range of APIs that nurture life and bequeath wellness. With the realities of the global economy now here to stay, it is now the era of only those who can leverage huge manufacturing infrastructure along with specialist knowledge and R&D focus," informed a company source.
He added that the company is on the process of setting up one more API manufacturing plant in Hyderabad in order to meet the increasing demands. Currently, Aurobindo owns 9 API/ intermediate units with over 5 million square meter area and more than 100 API manufacturing modules.
The company has a product portfolio of over 200 APIs with therapeutic segments across antibiotics, anti retrovirals, cardiovascular system (CVS), anti hypertensives, anti hyperlipoproteinemic, central nervous system (CNS), gastroenterological, anti diabetes and anti allergic products. The exports to about 100 countries with significant strategic marketing presence in Africa, South East Asia, Commonwealth of Independent States, USA, Europe and Latin America other than the domestic supplies in India. With 31 subsidiaries APL is located in strategic pharmaceutical markets like USA, UK, China, Thailand, Brazil, South Africa, Russia, Netherlands.
The company, which has recorded a turnover of Rs 1700 crore in API business last year, is expecting more than 20 per cent growth in the segment this year. Current year, the target is to achieve Rs 2000 crore turnover, added the official.